---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-230201"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2025-10-03T23:59:59+00:00"
generated_at: "2026-05-17T04:42:06.530343+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Alnylam enters $500M revolving credit facility maturing 2030

## Summary
- New $500M Revolving Credit Facility includes $150M letter of credit sublimit; available for working capital and general corporate purposes.
- Interest rates: Term SOFR plus 1.50%–2.50% (based on Total Leverage Ratio); commitment fee 0.20%–0.35% on unused commitments.
- Financial covenants: Total Net Leverage Ratio ≤ 3.75:1.00 and Consolidated Interest Coverage Ratio ≥ 3.00:1.00, tested quarterly.
- Maturity September 30, 2030; springing maturity if outstanding Springing Maturity Debt exceeds $630M or 100% of EBITDA.
- Guaranteed by material domestic subsidiaries and secured by substantially all assets, subject to customary exceptions and release conditions.

## SEC filing metadata
- accession: 0001193125-25-230201
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2025-10-03T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000119312525230201/0001193125-25-230201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000119312525230201/d19737d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-230201
- JSON: https://secwatch.observer/filing/0001193125-25-230201.json
- Plain text: https://secwatch.observer/filing/0001193125-25-230201.txt

## Key facts
- Debt Financings
  ALNYLAM PHARMACEUTICALS, INC. incurred revolving credit of $500.0 million revolving line of credit with Bank of America, N.A., as Administrative Agent at term SOFR rate plus an applicable margin between 1.50% and 2.50% maturing September 30, 2030.
  - Instrument: revolving credit
  - Principal: $500.0 million revolving line of credit
  - Counterparty: Bank of America, N.A., as Administrative Agent
  - Rate: term SOFR rate plus an applicable margin between 1.50% and 2.50%
  - Maturity: September 30, 2030
  - Event: incurrence
  source text: “Credit Agreement”) among the lenders party thereto, Bank of America, N.A., as Administrative Agent, and the other parties named therein. The Credit Agreement provides for a $500.0 million revolving line of credit (the “Revolving Credit Facility”), including a $150.0 million letter of credit sublimit. The Credit Agreement provides that the Company has the right at
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312525230201/0001193125-25-230201-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.